Welcome to our dedicated page for Cv Sciences news (Ticker: CVSI), a resource for investors and traders seeking the latest updates and insights on Cv Sciences stock.
CV Sciences, Inc. (OTCQB:CVSI) generates a steady stream of news as a consumer wellness company specializing in hemp extracts, nutraceuticals, and plant-based foods. Company announcements frequently cover financial results, product launches, regulatory developments, and capital markets activity, offering investors and observers insight into how the business is evolving across its wellness and plant-based platforms.
Regular earnings releases detail quarterly and annual performance, including product sales, gross margin trends, operating income or loss, cash balances, and non-GAAP measures such as Adjusted EBITDA. These updates often highlight the contribution of new products launched since early 2023 and discuss how state and federal regulatory environments for CBD affect B2B and B2C sales.
CV Sciences also issues news on new product introductions and brand extensions. Recent examples include the Ignite men’s performance formula under its wellness portfolio, the +PlusHLTH™ cannabinoid-free supplement line, expanded +PlusCBD™ sleep, calm, reserve, and pet products, and the launch of Lunar Fox, a plant-based company offering vegan alternatives to traditional animal-based proteins. These stories illustrate the company’s focus on innovation and diversification across supplements and plant-based foods.
Another recurring theme in CVSI news is regulatory and policy engagement. The company has publicly commented on federal actions related to CBD research and potential Medicare and Medicaid reimbursement for CBD products, as well as state-level legislation such as Texas Senate Bill 3. In addition, SEC Form 8-K filings and related press releases describe material financing agreements, secured promissory notes, and other capital structure developments.
For readers tracking CVSI, this news feed provides context on the company’s operating performance, product pipeline, regulatory posture, and financing activities. Returning to this page allows users to follow how CV Sciences’ hemp-derived wellness, supplement, and plant-based food strategies are reflected in its ongoing disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
CV Sciences, Inc. announced the launch of +PlusCBD™ Reserve Collection Extra Gummies on April 3, 2023. These gummies offer a potent blend of 25mg CBD and 5mg THC, aimed at enhancing wellness through improved sleep, recovery, and relaxation. The new formulation features organic ingredients, is gluten-free, soy-free, and vegan. With a focus on customizable wellness, the company positions these Extra Gummies as a higher THC alternative in their product range. CV Sciences emphasizes their commitment to high-quality manufacturing practices, third-party lab testing, and science-backed products, making them a top-selling brand in the hemp extract market.
CV Sciences reported revenue of $16.2 million for fiscal 2022, down from $20.0 million in 2021, reflecting a 19% decline primarily due to reduced retail sales and supply chain challenges. In Q4 2022, revenue rose 3% sequentially to $3.9 million, but was down 22% year-over-year. Gross margin decreased to 34.2% for the year compared to 43.0% in 2021. Operating expenses were cut by 54% to $12.4 million, resulting in a reduced operating loss of $6.8 million. The company generated positive cash flow of $0.2 million in Q4 2022, the best since Q2 2019. Initiatives for future growth include new product launches and cost efficiency improvements.
CV Sciences, Inc. (OTCQB:CVSI) announced it will release its financial results for the year and fourth quarter ended December 31, 2022, on March 29, 2023, before market open. A conference call with investors is scheduled for 7:00 a.m. PT the same day. The call can be accessed via telephone or through a webcast available on the Company's Investor Relations page. CV Sciences specializes in hemp extracts and other natural wellness products, with its PlusCBD™ brand being a top seller in the market, adhering to Good Manufacturing Practices (GMP). Investors can expect insights into the Company's financial performance and strategic direction during the call.
CV Sciences, Inc. (CVSI) announced the receipt of a formal patent grant from the Japan Patent Office for its innovative treatment method for smokeless tobacco addiction using a formulation containing CBD and nicotine. The patent covers a significant market, with global smoking cessation products projected to grow from $20 billion in 2021 to over $54 billion by 2031. The company aims to advance its drug candidate, CVSI-007, and seeks FDA approval for commercialization, highlighting the potential for improving healthcare outcomes for addiction treatment.
CV Sciences, Inc. (OTCQB:CVSI) has launched its new +PlusCBD™ Daily Balance THC-Free Gummies and Softgels, designed for consumers seeking the benefits of CBD without THC. Each gummy and softgel contains 25mg of 99.9% pure CBD isolate, is gluten-free, non-GMO, and third-party lab tested for safety. These products cater to a variety of users, including first responders and military personnel, who can benefit from exclusive discounts through the Daily Heroes program. With a focus on maintaining consumer wellness, the new line supports various wellness goals without the effects of THC.
CV Sciences, Inc. (OTCQB:CVSI) announced preliminary approval of a proposed settlement for a derivative lawsuit in Nevada, alleging breach of fiduciary duty. This lawsuit stemmed from events linked to a class action dismissed in July 2019. A settlement in principle was agreed upon in January 2022, with the U.S. District Court granting preliminary approval on February 7, 2023. A final hearing is scheduled for May 15, 2023. If approved, this settlement will resolve all claims without admitting wrongdoing by the company. Additionally, the settlement includes certain corporate reforms to be implemented within 60 days post-approval.